Cargando…

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series

BACKGROUND: Membranous nephropathy is a common cause of the nephrotic syndrome. Treatment with standard regimens fails to induce complete remission in most patients. We evaluated the efficacy of combination therapy with rituximab, low-dose, oral cyclophosphamide, and an accelerated prednisone taper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortazar, Frank B., Leaf, David E., Owens, Charles T., Laliberte, Karen, Pendergraft, William F., Niles, John L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286562/ https://www.ncbi.nlm.nih.gov/pubmed/28143416 http://dx.doi.org/10.1186/s12882-017-0459-z

Ejemplares similares

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal
por: Rojas-Rivera, Jorge Enrique, et al.
Publicado: (2019)

Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review
por: Jeon, Soo-Jee, et al.
Publicado: (2022)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
por: Cherukuri, Sundar V, et al.
Publicado: (2021)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
por: Xue, Cheng, et al.
Publicado: (2023)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Cyclophosphamide/prednisone: Various infections: case report
Publicado: (2021)

Cyclophosphamide/methylprednisolone/prednisone: No improvement: case report
Publicado: (2022)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
por: Wang, Yao-Wei, et al.
Publicado: (2023)

Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: Lu, Huijuan, et al.
Publicado: (2022)

Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial
por: Scolari, Francesco, et al.
Publicado: (2019)

Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
por: Go, Se‐Il, et al.
Publicado: (2016)

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
por: Svoboda, Jakub, et al.
Publicado: (2020)

Prednisone/rituximab: COVID-19: case report
Publicado: (2021)

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura
por: Wang, Jiuhe, et al.
Publicado: (2019)

Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide
por: Kikuchi, Taku, et al.
Publicado: (2017)

Eculizumab and Complement Activation in Anti−glomerular Basement Membrane Disease
por: Nithagon, Pravarut, et al.
Publicado: (2021)

Retracted: Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy
por: Mathrani, Vinod, et al.
Publicado: (2017)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome
por: Cortazar, Frank B, et al.
Publicado: (2018)

Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy Regimen
por: Kaur, Anahat, et al.
Publicado: (2019)

Prednisone/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Eptacog-α/prednisone/rituximab: No response: case report
Publicado: (2021)

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies
por: Laurencet, F M, et al.
Publicado: (1999)

The Efficacy of Cyclophosphamide Combined with Prednisone in Membranous Nephropathy Patients with Different Cytochrome P450 2B6 Gene Polymorphisms and Analysis of Factors Influencing the Efficacy
por: Zhang, Min, et al.
Publicado: (2022)

Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
por: Wang, Xiao-Pei, et al.
Publicado: (2016)

Tripterygium wilfordii multiglycosides combined with prednisone in the treatment of idiopathic membranous nephropathy: A protocol for a systematic review and meta-analysis
por: Jin, Yuxia, et al.
Publicado: (2020)

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
por: Lee, Eun Ju, et al.
Publicado: (2014)

Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
por: van Keep, Marjolijn, et al.
Publicado: (2016)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
por: Chen, Ping, et al.
Publicado: (2023)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
por: Lin, Wenshan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vkdi7ic7p73tm3kdl9j32trr15